**Protocol for the Examination of Specimens From Patients With Carcinomas of the Major Salivary Glands**

**Version:** 4.1.1.0

**Protocol Posting Date:** November 2021

**CAP Laboratory Accreditation Program Protocol Required Use Date:** March 2022

The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

**For accreditation purposes, this protocol should be used for the following procedures AND tumor types:**

|  |  |
| --- | --- |
| **Procedure** | **Description** |
| Resection | Includes specimens designated or containing parotid, submandibular, sublingual glands |
| **Tumor Type** | **Description** |
| Carcinoma | Includes primary salivary gland carcinoma and neuroendocrine carcinoma |

**This protocol is NOT required for accreditation purposes for the following:**

|  |
| --- |
| **Procedure** |
| **Biopsy** |
| **Primary resection specimen with no residual cancer (eg, following neoadjuvant therapy)** |
| **Cytologic specimens** |

**The following tumor types should NOT be reported using this protocol:**

|  |
| --- |
| **Tumor Type** |
| **Minor salivary gland carcinoma (consider the Lip and Oral Cavity, Nasal Cavity and Paranasal Sinuses, Pharynx, or Larynx protocols)** |
| **Sarcoma (consider the Soft Tissue protocol)** |
| **Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)** |

**Authors**

Raja R. Seethala, MD\*; Ilan Weinreb, MD; Martin J. Bullock, MD; Diane L. Carlson, MD; Robert L. Ferris, MD, PhD; Louis B. Harrison, MD; Jonathan B. McHugh, MD; Jason Pettus, MD; Mary S. Richardson, MD, DDS; Jatin Shah, MD; Lester D.R.. Thompson, MD; Bruce M. Wenig, MD.

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.
\* Denotes primary author.

**Accreditation Requirements**

This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

* Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
* Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
* Optional data elements are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

**Synoptic Reporting**

All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

* Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
* The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
* Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
	+ Anatomic site or specimen, laterality, and procedure
	+ Pathologic Stage Classification (pTNM) elements
	+ Negative margins, as long as all negative margins are specifically enumerated where applicable
* The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above.

**Summary of Changes**

**v 4.1.1.0**

* pN2 Note content updated
* Remodeled Preexisting pleomorphic adenoma component question
* Updated Explanatory Note G to include intraparotid lymph node metastasis
* Changed nested Margin questions from Conditional to Required

**Reporting Template**

**Protocol Posting Date: November 2021**

**Select a single response unless otherwise indicated.**

**CASE SUMMARY: (MAJOR SALIVARY GLANDS)**

**Standard(s)**: AJCC-UICC 8

**SPECIMEN (Note** [**A**](#1382)**)**

**Procedure (select all that apply)**

\_\_\_ Excision

\_\_\_ Parotidectomy, superficial

\_\_\_ Parotidectomy, deep

\_\_\_ Parotidectomy, total

\_\_\_ Parotidectomy, not specified

\_\_\_ Resection, submandibular gland

\_\_\_ Resection, sublingual gland

\_\_\_ Neck (lymph node) dissection (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not specified

**TUMOR**

**Tumor Focality**

\_\_\_ Unifocal

\_\_\_ Multifocal: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Tumor Site (Note** [**B**](#1383)**)**

\_\_\_ Parotid gland, superficial lobe: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Parotid gland, deep lobe: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Entire parotid gland: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Submandibular gland: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Sublingual gland: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Not specified

**Tumor Laterality**

\_\_\_ Right

\_\_\_ Left

\_\_\_ Bilateral

\_\_\_ Not specified

**Tumor Size**

\_\_\_ Greatest dimension in Centimeters (cm): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

**+Additional Dimension in Centimeters (cm): \_\_\_\_ x \_\_\_\_ cm**

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Preexisting Pleomorphic Adenoma Component (carcinoma ex pleomorphic adenoma) (Note** [**C**](#N4810)**)**

\_\_\_ Present

**Architectural Type**

*Required in addition to salivary carcinoma type*

\_\_\_ Carcinoma ex pleomorphic adenoma, minimally invasive

\_\_\_ Carcinoma ex pleomorphic adenoma, invasive

\_\_\_ Carcinoma ex pleomorphic adenoma, intracapsular (noninvasive)

\_\_\_ Carcinoma ex pleomorphic adenoma, extent cannot be determined

\_\_\_ Not applicable

**Histologic Type (Note** [**C**](#1384)**)**

\_\_\_ Mucoepidermoid carcinoma, low grade

\_\_\_ Mucoepidermoid carcinoma, intermediate grade

\_\_\_ Mucoepidermoid carcinoma, high grade

*# If multiple patterns present, select predominant pattern unless solid pattern is greater than 30%, in which case should select solid pattern.*

\_\_\_ Adenoid cystic carcinoma, tubular pattern#

**+Percentage of Solid Component**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

\_\_\_ Adenoid cystic carcinoma, cribriform pattern#

**+Percentage of Solid Component**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

\_\_\_ Adenoid cystic carcinoma, solid pattern#

**+Percentage of Solid Component**

\_\_\_ Specify percentage: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ %

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

\_\_\_ Acinic cell carcinoma

\_\_\_ Polymorphous adenocarcinoma, classic, low grade

\_\_\_ Polymorphous adenocarcinoma, classic, intermediate grade

\_\_\_ Polymorphous adenocarcinoma, classic, high grade

\_\_\_ Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), low grade

\_\_\_ Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), intermediate grade

\_\_\_ Polymorphous adenocarcinoma, cribriform (cribriform adenocarcinoma of salivary origin), high grade

\_\_\_ (Mammary analogue) Secretory carcinoma

\_\_\_ Salivary duct carcinoma

\_\_\_ Epithelial-myoepithelial carcinoma

\_\_\_ (Hyalinizing) clear cell carcinoma

\_\_\_ Adenocarcinoma, not otherwise specified, low grade

\_\_\_ Adenocarcinoma, not otherwise specified, intermediate grade

\_\_\_ Adenocarcinoma, not otherwise specified, high grade

\_\_\_ Basal cell adenocarcinoma

\_\_\_ Carcinosarcoma (true malignant mixed tumor)

\_\_\_ Intraductal carcinoma, low grade

\_\_\_ Intraductal carcinoma, high grade

\_\_\_ Lymphoepithelial carcinoma

\_\_\_ Myoepithelial carcinoma (malignant myoepithelioma)

\_\_\_ Oncocytic carcinoma

\_\_\_ Poorly differentiated neuroendocrine carcinoma, small cell type

\_\_\_ Poorly differentiated neuroendocrine carcinoma, large cell type

\_\_\_ Poorly differentiated carcinoma, undifferentiated

\_\_\_ Sebaceous adenocarcinoma

\_\_\_ Squamous cell carcinoma, primary

*Other*

\_\_\_ Other histologic type not listed (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Carcinoma, type cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Histologic Type Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**High Grade Transformation (if applicable)**

\_\_\_ Not applicable

\_\_\_ Not identified

\_\_\_ Present

**Macroscopic Tumor Extent (select all that apply)**

\_\_\_ No evidence of extraparenchymal extension

*pT3*

\_\_\_ Extraglandular soft tissue

*pT4a*

\_\_\_ Facial nerve

\_\_\_ Skin

\_\_\_ Ear canal

\_\_\_ Mandible

*pT4b*

\_\_\_ Skull base

\_\_\_ Pterygoid plates

\_\_\_ Carotid artery encasement

*Other*

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined

**Lymphovascular Invasion**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Perineural Invasion (Note** [**D**](#1386)**)**

\_\_\_ Not identified

\_\_\_ Present

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Tumor Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**MARGINS (Note** [**E**](#1385)**)**

**Margin Status**

\_\_\_ All margins negative for carcinoma

**Distance from Invasive Tumor to Closest Margin**

*Specify in Millimeters (mm)*

\_\_\_ Exact distance: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ mm

\_\_\_ Greater than: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ mm

\_\_\_ Less than 1 mm

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Closest Margin(s) to Carcinoma (if possible)**

\_\_\_ Specify location(s) of closest margin(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Carcinoma present at margin

**Margin(s) Involved by Carcinoma**

\_\_\_ Specify involved margin(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Margin Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**REGIONAL LYMPH NODES (Note** [**F**](#1387)**)**

**Regional Lymph Node Status**

\_\_\_ Not applicable (no regional lymph nodes submitted or found)

\_\_\_ Regional lymph nodes present

\_\_\_ All regional lymph nodes negative for tumor

\_\_\_ Tumor present in regional lymph node(s)

**Number of Lymph Nodes with Tumor**

\_\_\_ Exact number (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Laterality of Lymph Node(s) with Tumor**

\_\_\_ Ipsilateral (including midline): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Contralateral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Bilateral: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Size of Largest Nodal Metastatic Deposit**

*Specify in Centimeters (cm)*

\_\_\_ Not applicable

\_\_\_ Exact size: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ At least: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Greater than: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Less than: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ cm

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Extranodal Extension (ENE) (Note** [**F**](#1387)**)**

\_\_\_ Not identified

\_\_\_ Present

**+Distance of ENE from Lymph Node Capsule**

*Specify in Millimeters (mm)*

\_\_\_ Exact distance: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ mm

\_\_\_ Greater than 2 mm (macroscopic ENE)

\_\_\_ Less than or equal to 2 mm (microscopic ENE)

\_\_\_ Less than 1 mm

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Number of Lymph Nodes Examined**

\_\_\_ Exact number (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ At least (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined (explain): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**+Regional Lymph Node Comment: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**DISTANT METASTASIS**

**Distant Site(s) Involved, if applicable (select all that apply)**

\_\_\_ Not applicable

\_\_\_ Lung: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Bone: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Brain: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Liver: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_ Cannot be determined: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**PATHOLOGIC STAGE CLASSIFICATION (pTNM, AJCC 8th Edition) (Note** [**G**](#1388)**)**

*Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician’s responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.*

*The phrases in \*asterisks\* include clinical findings required for AJCC staging. This clinical information may not be available to the pathologist. However, if known, these findings should be incorporated into the pathologic staging.*

**TNM Descriptors (select all that apply)**

\_\_\_ Not applicable

\_\_\_ m (multiple primary tumors)

\_\_\_ r (recurrent)

\_\_\_ y (post-treatment)

**pT Category**

\_\_\_ pT not assigned (cannot be determined based on available pathological information)

\_\_\_ pT0: No evidence of primary tumor

\_\_\_ pTis: Carcinoma \*in situ\*

*# Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.*

\_\_\_ pT1: Tumor 2 cm or smaller in greatest dimension \*without extraparenchymal extension\*#

\_\_\_ pT2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension \*without extraparenchymal extension\*#

\_\_\_ pT3: Tumor larger than 4 cm and / or tumor \*having extraparenchymal extension\*#

*pT4: Moderately advanced or very advanced disease*

\_\_\_ pT4a: Moderately advanced local disease. Tumor invades skin, mandible, ear canal, and / or facial nerve.

\_\_\_ pT4b: Very advanced local disease. Tumor invades skull base and / or pterygoid plates and / or encases carotid artery

\_\_\_ pT4 (subcategory cannot be determined)

**pN Category# (Note** [**F**](#1387)**)**

*# Midline nodes are considered ipsilateral nodes.*

*Pathological ENE should be recorded as ENE(−) or ENE(+).*

*Measurement of the metastatic focus in the lymph nodes is based on the largest metastatic deposit size, which may include matted or fused lymph nodes.*

\_\_\_ pN not assigned (no nodes submitted or found)

\_\_\_ pN not assigned (cannot be determined based on available pathological information)

\_\_\_ pN0: No regional lymph node metastasis

\_\_\_ pN1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)

*pN2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastasis in multiple ipsilateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)*

\_\_\_ pN2a: Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)

\_\_\_ pN2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)

\_\_\_ pN2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-)

\_\_\_ pN2 (subcategory cannot be determined)

*pN3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)*

\_\_\_ pN3a: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)

\_\_\_ pN3b: Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)

\_\_\_ pN3 (subcategory cannot be determined)

**pM Category (required only if confirmed pathologically)**

\_\_\_ Not applicable - pM cannot be determined from the submitted specimen(s)

\_\_\_ pM1: Distant metastasis

**ADDITIONAL FINDINGS**

**+Additional Findings (select all that apply)**

\_\_\_ None identified

\_\_\_ Sialadenitis

\_\_\_ Tumor associated lymphoid proliferation (TALP)

\_\_\_ Other (specify): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**SPECIAL STUDIES**

*For reporting molecular testing and other cancer biomarker testing results, the CAP Head and Neck Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report.*

**COMMENTS**

**Comment(s): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Explanatory Notes**

**A. Scope of Guidelines**

The reporting of major salivary gland cancer is facilitated by the provision of a case summary illustrating the features required for comprehensive patient care. However, there are many cases in which the individual practicalities of applying such a case summary may not be straightforward. Common examples include finding the prescribed number of lymph nodes, trying to determine the levels of the radical neck dissection, and determining if isolated tumor cells in a lymph node represent metastatic disease. Case summaries have evolved to include clinical, radiographic, morphologic, immunohistochemical, and molecular results in an effort to guide clinical management. Adjuvant and neoadjuvant therapy can significantly alter histologic findings, making accurate classification an increasingly complex and demanding task. This protocol tries to remain simple while still incorporating important pathologic features as proposed by the American Joint Committee on Cancer (AJCC) cancer staging manual,[1](#5159) the World Health Organization (WHO) classification of tumors, the TNM classification, the American College of Surgeons Commission on Cancer, and the International Union on Cancer (UICC). This protocol is to be used as a guide and resource, an adjunct to diagnosing and managing cancers of the oral cavity in a standardized manner. It should not be used as a substitute for dissection or grossing techniques and does not give histologic parameters to reach the diagnosis. Subjectivity is always a factor, and elements listed are not meant to be arbitrary but are meant to provide uniformity of reporting across all the disciplines that use the information. It is a foundation of practical information that will help to meet the requirements of daily practice to benefit both clinicians and patients alike.

References

1. Gress DM, Edge SB, Greene FL, et al. Principles of cancer staging. In: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.

**B. Primary Site (Figure 1)**

The classification applies only to carcinomas of the major salivary glands: parotid, submandibular (submaxillary), and sublingual glands.[1](#5160) Tumors arising in minor salivary glands (mucous-secreting glands in the lining membrane of the upper aerodigestive tract) are staged according to the classification schemes corresponding to the anatomic sites in which they reside, eg, oral cavity, pharynx, sinonasal tract.



**Figure 1**. Anatomy of the major salivary glands. From: Gray’s Anatomy. 39th ed. Edinburgh: Elsevier Churchill Livingstone; 2005. Reproduced with permission © Elsevier.

References

1. Lydiatt WM, Mukherji SK, O'Sullivan B, Patel SG, Shah JP. Major salivary glands. In: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.

**C. Histologic Type and Grade**

The histologic classification recommended is the WHO classification of salivary gland tumors.[1](#5161)

Mucoepidermoid carcinoma

Adenoid cystic carcinoma

Acinic cell carcinoma

Polymorphous adenocarcinoma

(Mammary analogue) secretory carcinoma

Salivary duct carcinoma

Carcinoma ex pleomorphic adenoma

Epithelial-myoepithelial carcinoma

(Hyalinizing) clear cell carcinoma

Adenocarcinoma, not otherwise specified

Basal cell adenocarcinoma

Carcinosarcoma

Intraductal carcinoma

Lymphoepithelial carcinoma

Myoepithelial carcinoma

Oncocytic carcinoma

Poorly differentiated carcinoma

Large cell neuroendocrine carcinoma

Small cell neuroendocrine carcinoma

Undifferentiated carcinoma

Sebaceous adenocarcinoma

Squamous cell carcinoma

# Includes cystadenocarcinoma, intestinal type adenocarcinoma, and mucinous adenocarcinoma

In this current classification, sialoblastoma is designated as a tumor of uncertain malignant potential.  Metastasizing pleomorphic adenoma has been collapsed under pleomorphic adenoma.[1](#5161)  Since the biologic behavior of these still overlaps with the other malignant tumors, these can be reported under “other.”

**Histologic Grade**

The histologic (microscopic) grading of salivary gland carcinomas has been shown to be an independent predictor of behavior and plays a role in optimizing therapy. Further, there is often a positive correlation between histologic grade and clinical stage.[2,](#5162)[3,](#5163)[4,](#5164)[5](#5165) However, most salivary gland carcinoma types have an intrinsic biologic behavior, and attempted application of a universal grading scheme is merely a crude surrogate.[4](#5164) Thus, a generic grading scheme is no longer recommended for salivary gland carcinomas.[6](#5166) Carcinoma types for which grading systems exist and are relevant are incorporated into histologic type. The 3 major categories that are amenable to grading include adenoid cystic carcinoma, mucoepidermoid carcinoma, and adenocarcinoma, not otherwise specified.[3,](#5163)[4,](#5164)[7](#5167)

In some carcinomas, histologic grading may be based on growth pattern, such as in adenoid cystic carcinoma, for which a histologic high-grade variant has been recognized based on the percentage of solid growth.[7](#5167)Those adenoid cystic carcinomas showing 30% or greater of solid growth pattern are considered to be histologically high-grade carcinomas. The histologic grading of mucoepidermoid carcinoma includes a combination of growth pattern characteristics (eg, cystic, solid, neurotropism) and cytomorphologic findings (eg, anaplasia, mitoses, necrosis).[8,](#5168)[9,](#5169)[10](#5170) Adenocarcinomas, not otherwise specified, do not have a formalized grading scheme and are graded intuitively based on cytomorphologic features.[4](#5164)  Polymorphous adenocarcinomas are to be graded as per current WHO recommendations, though these are also graded intuitively as there are no listed criteria.

Carcinoma ex pleomorphic adenoma is subclassifed by histologic type and or grade and extent of invasion, the latter including minimally invasive, widely invasive, and intracapsular (noninvasive) cancers. Previously the cut-off for minimal invasion was designated as 1.5 mm; however, more recent studies have shown a favorable prognosis even with cut-offs of 4 mm to 6 mm.[11](#5171) Thus, there is no agreement on an optimal cut-off. However, from a practical standpoint, the terms intracapsular and minimally invasive should only be applied to uninodular tumors (as opposed to carcinomas arising in multinodular recurrent pleomorphic adenomas) with a well-delineated interface for which the entire lesional border has been microscopically evaluated. Prognosis has been linked to degree of invasion with noninvasive and minimally invasive cancers apparently having a better prognosis than invasive cancers.[4,](#5164)[11,](#5171)[12](#5172)

References

1. El-Naggar AK. Introduction. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, eds. WHO Classification of Head and Neck Tumours. 4th ed. Geneva, Switzerland: WHO Press; 2017:160-162.
2. Spiro RH, Thaler HT, Hicks WF, Kher UA, Huvos AH, Strong EW. The importance of clinical staging of minor salivary gland carcinoma. Am J Surg. 1991;162(4):330-336.
3. Spiro RH, Huvos AG, Strong EW. Adenocarcinoma of salivary origin. Clinicopathologic study of 204 patients. Am J Surg. 1982;144(4):423-431.
4. Seethala RR. Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol. 2011;18(1):29-45.
5. Kane WJ, McCaffrey TV, Olsen KD, Lewis JE. Primary parotid malignancies. A clinical and pathologic review. Arch Otolaryngol Head Neck Surg. 1991;117(3):307-315.
6. Lydiatt WM, Mukherji SK, O'Sullivan B, Patel SG, Shah JP. Major salivary glands. In: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
7. Szanto PA, Luna MA, Tortoledo ME, White RA. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer. 1984;54(6):1062-1069.
8. Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN. A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg Pathol. 2010;34(8):1106-1121.
9. Brandwein MS, Ivanov K, Wallace DI, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol. 2001;25(7):835-845.
10. Auclair PL, Goode RK, Ellis GL. Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. Cancer. 1992;69(8):2021-2030
11. Williams MD, Ihrler S, Seethala RR. Carcinoma ex pleomorphic adenoma. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, eds. WHO Classification of Head and Neck Tumours. 4th ed. Geneva, Switzerland: WHO Press; 2017:176-177.
12. Brandwein M, Huvos AG, Dardick I, Thomas MJ, Theise ND. Noninvasive and minimally invasive carcinoma ex mixed tumor: a clinicopathologic and ploidy study of 12 patients with major salivary tumors of low (or no?) malignant potential. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81(6):655-664.

**D. Perineural Invasion**

The presence of perineural invasion (neurotropism) is an important predictor of poor prognosis in head and neck cancer of virtually all sites.[1](#5176) The majority of studies evaluating the influence of perineural invasion on therapy and prognosis are limited to head and neck squamous cell carcinoma. However, relative to salivary gland carcinomas, facial nerve dysfunction and perineural involvement are factors influencing the indication for neck dissection, postoperative radiation therapy, and survival rate. Perineural invasion (neurotropism) in the primary salivary gland carcinomas, especially the facial nerve, is associated with recurrent tumor[2](#5177) and decreased survival. Further, facial nerve involvement by carcinoma has been found to be predictive of occult metastases.[3](#5178)Among other prognostic indicators, perineural invasion in minor salivary gland tumors has been shown to be statistically significant to the outcome.[4](#5179) Given the significance relative to prognosis and treatment, perineural invasion is a required data element in the reporting of salivary gland carcinomas.

References

1. Smith BD, Haffty BG. Prognostic factoris in patients with head and neck cancer. In: Harrison LB, Sessions RB, Hong WK, eds. Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: Lippincott Williams and Wilkins; 2009:51-75.
2. Ali S, Palmer FL, Yu C, et al. A predictive nomogram for recurrence of carcinoma of the major salivary glands. JAMA Otolaryngol Head Neck Surg. 2013;139(7):698-705.
3. Frankenthaler RA, Luna MA, Lee SS, et al. Prognostic variables in parotid gland cancer. Arch Otolaryngol Head Neck Surg. 1991;117(11):1251-1256.
4. Copelli C, Bianchi B, Ferrari S, Ferri A, Sesenna E. Malignant tumors of intraoral minor salivary glands. Oral Oncol. 2008;44(7):658-663.

**E. Surgical Margins**

Complete surgical excision to include cancer-free surgical margins is the primary mode of therapy for salivary gland cancers, as retrospective studies have shown an increased risk for recurrence and decreased survival with positive surgical margins.[1,](#5173)[2,](#5174)[3](#5175) The need for additional surgery is determined on the basis of histopathologic review; positive surgical margins are an indication for additional resection to ensure total tumor removal.

**Orientation of Specimen**

Complex specimens should be examined and oriented with the assistance of attending surgeons. Direct communication between the surgeon and pathologist is a critical component in specimen orientation and proper sectioning. Whenever possible, the tissue examination request form should include a drawing of the resected specimen showing the extent of the tumor and its relation to the anatomic structures of the region. The lines and extent of the resection can be depicted on preprinted adhesive labels and attached to the surgical pathology request forms.

References

1. Tran L, Sadeghi A, Hanson D, et al. Major salivary gland tumors: treatment results and prognostic factors. Laryngoscope. 1986;96(10):1139-1144.
2. Vander Poorten VL, Balm AJ, Hilgers FJ, et al. The development of a prognostic score for patients with parotid carcinoma. Cancer. 1999;85(9):2057-2067.
3. Amini A, Waxweiler TV, Brower JV, et al. Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg. 2016;142(11):1100-1110.

**F. Lymph Nodes**

**Measurement of Tumor Metastasis**

The cross-sectional diameter of the largest lymph node metastasis (not the lymph node itself) is measured in the gross specimen at the time of macroscopic examination or, if necessary, on the histologic slide at the time of microscopic examination.[1,](#5180)[2](#5181)

**Special Procedures for Lymph Nodes**

At the current time, no additional special techniques should be used other than routine histology for the assessment of nodal metastases. Immunohistochemistry and polymerase chain reaction (PCR) to detect isolated tumor cells are considered investigational techniques at this time.

**Lymph Node Number**

For assessment of pN, a selective neck dissection will ordinarily include 10 or more lymph nodes, and a comprehensive neck dissection (radical or modified radical neck dissection) will ordinarily include 15 or more lymph nodes. Examination of fewer tumor-free nodes still mandates a pN0 designation.

**Regional Lymph Nodes (pN0): Isolated Tumor Cells**

Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. While the generic recommendation is that for lymph nodes with ITCs found by either histologic examination, immunohistochemistry, or nonmorphologic techniques (eg, flow cytometry, DNA analysis, PCR amplification of a specific tumor marker), they should be classified as N0 or M0, respectively.[3,](#5182)[4](#5183) Evidence for the validity of this practice in head and neck squamous cell carcinoma and other histologic subtypes is lacking. In fact, rare studies relevant to head and neck sites indicate that isolated tumor cells may actually be a poor prognosticator in terms of local control.[5](#5184)

For purposes of pathologic evaluation, lymph nodes are organized by levels, as shown in Figure 2.

**Classification of Neck Dissection**

1. Radical neck dissection
2. Modified radical neck dissection, internal jugular vein and/or sternocleidomastoid muscle spared
3. Selective neck dissection (SND), as specified by the surgeon (Figure 3), defined by dissection of less than the 5 traditional levels of a radical and modified radical neck dissection. The following dissections are now under this category[2,](#5181)[6,](#5185)[7](#5186):
	1. Supraomohyoid neck dissection
	2. Posterolateral neck dissection
	3. Lateral neck dissection
	4. Central compartment neck dissection
4. Superselective neck dissection (SSND), a relatively new term defined by dissection of the fibrofatty elements of 2 or less levels.[8](#5187)
5. Extended radical neck dissection, as specified by the surgeon



**Figure 2.** The six sublevels of the neck for describing the location of lymph nodes within levels I, II, and V. Level IA, submental group; level IB, submandibular group; level IIA, upper jugular nodes along the carotid sheath, including the subdigastric group; level IIB, upper jugular nodes in the submuscular recess; level VA, spinal accessory nodes; and level VB, the supraclavicular and transverse cervical nodes. From: Flint PW, et al, eds. Cummings Otolaryngology: Head and Neck Surgery. 5th ed. Philadelphia, PA; Saunders: 2010. Reproduced with permission © Elsevier.

In order for pathologists to properly identify these nodes, they must be familiar with the terminology of the regional lymph node groups and with the relationships of those groups to the regional anatomy. Which lymph node groups surgeons submit for histopathologic evaluation depends on the type of neck dissection they perform. Therefore, surgeons must supply information on the types of neck dissections that they perform and the details of the local anatomy in the specimens they submit for examination or, in other manners, orient those specimens for pathologists.

If it is not possible to assess the levels of lymph nodes (for instance, when the anatomic landmarks in the excised specimens are not specified), then the lymph node levels may be estimated as follows: level II, upper third of internal jugular (IJ) vein or neck specimen; level III, middle third of IJ vein or neck specimen; level IV, lower third of IJ vein or neck specimen, all anterior to the sternocleidomastoid muscle.

**Level I. Submental Group (Sublevel IA)**

Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone.

**Level I. Submandibular Group (Sublevel IB)**

Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle and the body of the mandible. The submandibular gland is included in the specimen when the lymph nodes within this triangle are removed.

**Level II. Upper Jugular Group (Sublevels IIA and IIB)**

Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve extending from the level of the carotid bifurcation (surgical landmark) or hyoid bone (clinical landmark) to the skull base. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level III. Middle Jugular Group**

Lymph nodes located around the middle third of the internal jugular vein extending from the carotid bifurcation superiorly to the omohyoid muscle (surgical landmark), or cricothyroid notch (clinical landmark) inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level IV. Lower Jugular Group**

Lymph nodes located around the lower third of the internal jugular vein extending from the omohyoid muscle superiorly to the clavicle inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

**Level V. Posterior Triangle Group (Sublevels VA and VB)**

This group comprises predominantly the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes are also included in this group. The posterior boundary of the posterior triangle is the anterior border of the trapezius muscle, the anterior boundary of the posterior triangle is the posterior border of the sternocleidomastoid muscle, and the inferior boundary of the posterior triangle is the clavicle.

**Level VI. Anterior (Central) Compartment**

Lymph nodes in this compartment include the pre- and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerve. The superior boundary is the hyoid bone, the inferior boundary is the suprasternal notch, the lateral boundaries are the common carotid arteries, and the posterior boundary by the prevertebral fascia.

**Level VII. Superior Mediastinal Lymph Nodes**

Metastases at level VII are considered regional lymph node metastases; all other mediastinal lymph node metastases are considered distant metastases.

Lymph node groups removed from areas not included in the above levels, eg, scalene, suboccipital, and retropharyngeal, should be identified and reported from all levels separately. Midline nodes are considered ipsilateral nodes.

**Extranodal Extension**

The status of cervical lymph nodes is the single most important prognostic factor in aerodigestive cancer. For uniformity and based on existing evidence (albeit a much smaller scale)[9](#5188), these principles are applied to salivary gland carcinomas as well. All macroscopically negative or equivocal lymph nodes should be submitted in toto. Grossly positive nodes may be partially submitted for microscopic documentation of metastasis. Reporting of lymph nodes containing metastasis should include whether there is presence or absence of extranodal extension (ENE),[10](#5189) which is now part of N staging. This finding consists of extension of metastatic tumor, present within the confines of the lymph node, through the lymph node capsule into the surrounding connective tissue, with or without associated stromal reaction. A distance of extension from the native lymph node capsule is now suggested (but not yet required) with the proposed stratification of ENE into ENEma (>2 mm) and ENEmi  (≤2 mm).[11,](#5190)[12,](#5191)[13,](#5192)[14](#5193) However, pitfalls in the measurement (ie, in larger, matted lymph nodes, in nodes post fine-needle aspiration, and in nodes with near total replacement of lymph node architecture) and the disposition of soft tissue deposits is still not resolved. In general, absence of ENE in a large (>3 cm) lymph node, especially with traversing fibrous bands, should be viewed with skepticism. Soft tissue deposits for lymph node metastases based on limited studies appear to be the equivalent of a positive lymph node with ENE and should be recorded as such.[15](#5194)

References

1. Smith BD, Haffty BG. Prognostic factoris in patients with head and neck cancer. In: Harrison LB, Sessions RB, Hong WK, eds. Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: Lippincott Williams and Wilkins; 2009:51-75.
2. Seethala RR. Current state of neck dissection in the United States. Head Neck Pathol. 2009;3(3):238-245.
3. Sobin LH, Gospodarowicz MK, Wittekind CH, eds. TNM Classification of Malignant Tumours. New York: Wiley-Liss; 2009.
4. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer. 2003;98(12):2740-2741.
5. Broglie MA, Haerle SK, Huber GF, Haile SR, Stoeckli SJ. Occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinomas: Impact on survival. Head Neck. 2013;35(5):660-666.
6. Ferlito A, Robbins KT, Shah JP, et al. Proposal for a rational classification of neck dissections. Head Neck. 2011;33(3):445-450.
7. Robbins KT, Shaha AR, Medina JE, et al. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 2008;134(5):536-538.
8. Suarez C, Rodrigo JP, Robbins KT, et al. Superselective neck dissection: rationale, indications, and results. Eur Arch Otorhinolaryngol. 2013.
9. Erovic BM, Shah MD, Bruch G, et al. Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis. J Otolaryngol Head Neck Surg. 2015;44:43.
10. Ebrahimi A, Gil Z, Amit M. International Consortium for Outcome Research (ICOR) in Head and Neck Cancer. Primary tumor staging for oral cancer and a proposed modification incorporating depth of invasion: an international multicenter retrospective study. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1138-1148.
11. Ridge JA, Lydiatt WM, Patel SG, et al. Lip and oral cavity. In: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
12. Ebrahimi A, Clark JR, Amit M, et al. Minimum nodal yield in oral squamous cell carcinoma: defining the standard of care in a multicenter international pooled validation study. Ann Surg Oncol. 2014;21(9):3049-3055.
13. Prabhu RS, Hanasoge S, Magliocca KR, et al. Extent of pathologic extracapsular extension and outcomes in patients with nonoropharyngeal head and neck cancer treated with initial surgical resection. Cancer. 2014;120(10):1499-1506.
14. Dunne AA, Muller HH, Eisele DW, Kessel K, Moll R, Werner JA. Meta-analysis of the prognostic significance of perinodal spread in head and neck squamous cell carcinomas (HNSCC) patients. Eur J cancer. 2006;42(12):1863-1868.
15. Jose J, Moor JW, Coatesworth AP, Johnston C, MacLennan K. Soft tissue deposits in neck dissections of patients with head and neck squamous cell carcinoma: prospective analysis of prevalence, survival, and its implications. Arch Otolaryngol Head Neck Surg. 2004;130(2):157-160.

**G. TNM and Stage Groupings**

The protocol recommends the TNM staging system of the American Joint Committee on Cancer and the International Union Against Cancer for salivary gland cancer.[1](#5195)

There are no significant changes to T stage in the AJCC 8th edition for major salivary gland. Carcinomas for which the Tis designation may be applied include some intracapsular carcinomas ex pleomorphic adenoma, and intraductal carcinomas.  However, as with squamous cell carcinoma of the head and neck sites (excluding nasopharynx and human papillomavirus (HPV)-related carcinomas), N stage now incorporates extranodal extension.[1](#5195)

**Extraparenchymal Extension**

Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues or nerve (T1, T2, T3), except those listed under T4a and 4b. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.[1](#5195)

**Intraparotid Lymph Nodes**

By convention, a tumor arising from an intranodal parotid tissue should not be considered a metastasis (N0).  However, if the tumor has spread via lymphatics into an intraparotid lymph node this would be considered positive with respect to determining N category.[2](#R20221)

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and based on clinical stage information supplemented/modified by operative findings and gross and microscopic evaluation of the resected specimens.[3](#5196) pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

The “a” prefix designates the stage determined at autopsy: aTNM.

**Additional Descriptors**

Residual Tumor (R)

Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.

RX       Presence of residual tumor cannot be assessed

R0        No residual tumor

R1        Microscopic residual tumor

R2        Macroscopic residual tumor

 For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

References

1. Lydiatt WM, Mukherji SK, O'Sullivan B, Patel SG, Shah JP. Major salivary glands. In: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
2. Guntinas-Lichius O, Thielker J, Robbins KT, Olsen KD, Shaha AR, Mäkitie AA, de Bree R, Vander Poorten V, Quer M, Rinaldo A, Kowalski LP, Rodrigo JP, Hamoir M, Ferlito A. Prognostic role of intraparotid lymph node metastasis in primary parotid cancer: Systematic review. Head Neck. 2021 Mar;43(3):997-1008. doi: 10.1002/hed.26541. Epub 2020 Nov 9. PMID: 33169420.
3. Gress DM, Edge SB, Greene FL, et al. Principles of cancer staging. In: Amin MB, ed. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.